AI assistant
CSL Ltd. — Board/Management Information 2021
Aug 16, 2021
17854_rns_2021-08-16_79e03081-3a24-4677-ac86-e33d172d605e.pdf
Board/Management Information
Open in viewerOpens in your device viewer
For immediate release
17 August 2021
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Appointment of New Non-Executive Director
CSL Limited (ASX:CSL; USOTC:CSLLY) today announces the appointment of Professor Duncan Maskell as an independent Non-executive Director, to be effective from 18 August 2021.
CSL’s Chair, Dr Brian McNamee AO said “Professor Maskell is an exceptional addition to the CSL Board. He brings wide-ranging international experience in science and commerce, developed across a rich 30-year career in research, academia and entrepreneurship. These areas represent the core of what we do at CSL and his contribution will strengthen the Board’s range of experience.”
Professor Maskell is the Vice-Chancellor of the University of Melbourne. Prior to this he was Senior Pro-Vice-Chancellor at the University of Cambridge in the United Kingdom, where he was responsible for planning and resources for the institution’s operations with an annual turnover of approximately GBP2 billion.
A research specialist in infectious diseases, Professor Maskell has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech.
Professor Maskell has had extensive experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-executive Director of Genus Plc, a FTSE 250 company.
Professor Maskell holds a Master of Arts and a Doctor of Philosophy from the University of Cambridge.
Authorised by Fiona Mead Company Secretary
==> picture [99 x 7] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Page 2
FURTHER INFORMATION
For further information, please contact:
Investors: Media: Mark Dehring Jimmy Baker Head of Investor Relations Communications, Asia Pacific CSL Limited CSL Limited Telephone: +613 9389 3407 Mobile +61 450 909 211 Email: [email protected] Email: [email protected]
® Trademarks of CSL Limited or its affiliates.
==> picture [99 x 7] intentionally omitted <==